MP21-16 NOVEL MOLECULARLY TARGETED COMBINATION FOR RENAL CELL CARCINOMA

INTRODUCTION AND OBJECTIVES:Despite many available treatments, >90% of metastatic renal cell carcinoma (mRCC) patients die within 5 years. Due to its modest efficacy, Sorafenib (SF) is a second lin...